Cagrilintide Weight loss peptides Pure Cagrilintide raw powder Pharmacy Grade 99% CAS 1415456-99-3

Sales manager：Luna
WhatsApp：+852 93127825
Email：luna2206866@gmail.com

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insu from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insu, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy. Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.

Appearance: Powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

1. R&D company:  Novo Nordisk

2. Type of drug:  Long-acting amylin analog

3. Mechanism of action:  Achieve weight loss by delaying gastric emptying, reducing energy intake and regulating food choices and preferences. It can also inhibit postprandial glucagon release and exert glucose regulation.

Clinical studies:
In clinical studies of combined use with semaglutide 2.4 mg, the average weight loss of subjects at week 20 (15.7%, 17.1%) was greater than that of the placebo group (9.8%). *A study published in The Lancet showed that cagrilintide combined with semaglutide 2.4 mg is safe and effective for weight control.
R&D stage: It has entered the Phase III clinical research stage, targeting overweight or obese patients for weight loss treatment.
In short, cagrilintide is a drug with significant weight loss effect and is currently in the clinical research stage. It achieves weight loss by regulating amylin levels, providing a new treatment option for obese patients.

FengMing Peptide Trading Technology Co., Ltd.,   located in Tianjin City, is a high-tech enterprise focusing on the research, development and production of peptide products. The company was established in recent years and is committed to applying advanced biotechnology to the health industry to meet the market's demand for high-quality, high-efficiency peptide products.
As a leading peptide manufacturer, FM Technology has a R&D team composed of senior scientists and engineers, which continues to explore and innovate, and is committed to developing safer, more effective, and more market-competitive peptide products. The company's main products cover but are not limited to pharmaceutical grade, food grade and cosmetic grade and other fields, and are widely used in many aspects such as health care, disease prevention, beauty and skin care.

In terms of production technology, FM Technology adopts internationally advanced production equipment and technology to ensure that every aspect of the product, from raw material selection, production and processing to finished product packaging, strictly follows relevant national standards and specifications to ensure product quality and safety. At the same time, the company has also established a complete quality management system and after-sales service system to provide customers with all-round, one-stop service support.
FM Technology adheres to the corporate philosophy of "technology leads health, quality creates the future" and always adheres to the development path of people-oriented and technological innovation. The company not only focuses on product quality and innovation, but also actively fulfills its social responsibilities and is committed to promoting the development and progress of the health industry.

In the future, FengMing Peptide Trading Technology Co., Ltd. will continue to delve into the field of peptide product research and development, continue to explore and make breakthroughs, and strive to become a leader in the global peptide industry and make greater contributions to human health.